AAV2 Capsid Variants for Blood-Brain Barrier Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current recombinant AAV vectors face limitations such as low transduction efficiency, restricted tissue tropisms, and inability to cross the blood-brain barrier, hindering their application in therapeutic gene delivery, especially for disorders affecting the central nervous system.
Innovation Solution
Development of AAV2 capsid protein variants with specific amino acid substitutions that enhance tissue targeting properties, allowing for efficient crossing of the blood-brain barrier and transduction of deep brain structures, including neurons and glial cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If wild-type AAV2 capsid protein is used, then the vector maintains natural tissue tropism, but transduction efficiency in deep brain structures is low
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid residues at positions 32, 39, 66, 70, 115, 149, 151, and 153 of the AAV2 capsid protein. These specific parameter changes in the capsid structure enable the vector to cross the blood-brain barrier and transduce deep brain structures, thereby improving transduction efficiency while maintaining controlled tissue tropism through rational design.
2Adaptability or versatility
If AAV vectors are designed for broad tissue tropism, then applicability expands, but ability to cross blood-brain barrier is lost
Solution Approach 1:
The patent applies local quality by making specific amino acid substitutions at particular positions (32, 39, 66, 70, 115, 149, 151, 153) of the capsid protein while leaving the rest of the structure intact. This localized modification approach grants the vector the specific ability to cross the blood-brain barrier while preserving other important functional properties, achieving both broad applicability and BBB penetration capability.
3Productivity
If capsid protein sequence is highly modified, then transduction efficiency improves, but fidelity to wild-type function decreases
Solution Approach 1:
The patent systematically modifies specific amino acid parameters at positions 32, 39, 66, 70, 115, 149, 151, and 153 to improve transduction efficiency. By carefully selecting which parameters to change and which to preserve, the invention achieves enhanced brain transduction while maintaining sufficient sequence identity to wild-type AAV2 for proper capsid assembly and function.
Data Source
AI summary
Aspects of the disclosure relate to compositions and methods for delivering a transgene (e.g., a transgene encoding one or more gene products) to a target cell (e.g., a brain cell). The disclosure is based, in part, on adeno-associated virus (AAV) capsid proteins comprising one or more amino acid substitutions, and methods of using the same for delivery of a transgene to tissues and cells of the central nervous system (e.g., brain cells).